|
Market Closed -
Nasdaq
16:00:00 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 11.23 USD | +0.99% |
|
+2.56% | -44.84% |
| 08-11 | BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 | MT |
| 08-03 | Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 223M | - | - | - | ||
| 70.64B | |||||
| 66.11B | |||||
| 27.98B | - | ||||
| 26.51B | - | ||||
| 26.44B |
Select your edition
All financial news and data tailored to specific country editions
